Pushing the limits of radiation therapy for prostate cancer: Where do we go next?

Seminars in Oncology

Volumn 40, Issue 3, 2013, Pages 297-307

  Mishra, Mark V ^a   Showalter, Timothy N ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; CABAZITAXEL; DOCETAXEL; FLUORODEOXYGLUCOSE F 18; IPILIMUMAB; PLACEBO; PROTON; SIPULEUCEL T;

ARTICLE; BRACHYTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CONE BEAM COMPUTED TOMOGRAPHY; CRYOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTODYNAMIC THERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTON RADIATION; PROTON THERAPY; RADIATION DOSE DISTRIBUTION; RADIOFREQUENCY ABLATION; STEREOTACTIC BODY RADIATION THERAPY; TUMOR ABLATION;

BRACHYTHERAPY; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS; PROTON THERAPY; RADIOSURGERY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, IMAGE-GUIDED;

EID: 84879447930     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.04.005     Document Type: Article

References (83)

1. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487
2. S.T. Peeters, W.D. Heemsbergen, and P.C. Koper Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 2006 1990 1996
3. A.L. Zietman, K. Bae, and J.D. Slater Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09 J Clin Oncol 28 2010 1106 1111
4. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74
5. J.E. Bekelman, N. Mitra, and J. Efstathiou Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer Int J Radiat Oncol Biol Phys 81 2011 e325 e334
6. S. Kim, S. Shen, and D.F. Moore Late gastrointestinal toxicities following radiation therapy for prostate cancer Eur Urol 60 2011 908 916
7. E.M. Horwitz, K. Bae, and G.E. Hanks Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
8. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
9. C.U. Jones, D. Hunt, and D.G. McGowan Radiotherapy and short-term androgen deprivation for localized prostate cancer N Engl J Med 365 2011 107 118
10. J.D. Slater, L.T. Yonemoto, and C.J. Rossi Jr Conformal proton therapy for prostate carcinoma Int J Radiat Oncol Biol Phys 42 1998 299 304
11. M. Choi, and A.Y. Hung Technological advances in radiation therapy for prostate cancer Curr Urol Rep 11 2010 172 179
12. W.U. Shipley, J.E. Tepper, and G.R. Prout Jr Proton radiation as boost therapy for localized prostatic carcinoma JAMA 241 1979 1912 1915
13. F.M. Khan The physics of radiation therapy 4th ed 2010 Lippincott Williams & Wilkins Philadelphia
14. B. Larsson, L. Leksell, and B. Rexed The high-energy proton beam as a neurosurgical tool Nature 182 1958 1222 1223
15. M. Goitein, and J.D. Cox Should randomized clinical trials be required for proton radiotherapy? J Clin Oncol 26 2008 175 176
16. L. Gunderson, and J. Tepper Clinical radiation oncology 3rd ed 2011 Saunders Philadelphia 365 375
17. Y. Kase, H. Yamashita, and H. Fuji A treatment planning comparison of passive-scattering and intensity-modulated proton therapy for typical tumor sites J Radiat Res 53 2012 272 280
18. J.J. Coen, and A.L. Zietman Proton radiation for localized prostate cancer Nat Rev Urol 6 2009 324 330
19. A. Trofimov, P.L. Nguyen, and J.J. Coen Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison Int J Radiat Oncol Biol Phys 69 2007 444 453
20. J.J. Coen, K. Bae, and A.L. Zietman Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology phase II study 03-12 Int J Radiat Oncol Biol Phys 81 2010 1005 1009
21. M.J. Zelefsky, E.J. Levin, and M. Hunt Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 70 2008 1124 1129
22. G.O. De Meerleer, V.H. Fonteyne, and L. Vakaet Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control Radiother Oncol 82 2007 160 166
23. P. Kupelian, T. Willoughby, and A. Mahadevan Multi-institutional clinical experience with the Calypso System in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy Int J Radiat Oncol Biol Phys 67 2007 1088 1098
24. M.V. Mishra, R. Shirazi, and W.L. Barrett Incidence and clinical course of hemorrhagic radiation proctitis after iodine-125 prostate brachytherapy Clin Genitourinary Cancer 5 2007 397 400
25. S.A. Vora, W.W. Wong, and S.E. Schild Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 68 2007 1053 1058
26. P. Ghadjar, O. Matzinger, and B. Isaak Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer Radiother Oncol 91 2009 237 242
27. P. Ghadjar, C.A. Rentsch, and B. Isaak Urethral toxicity vs. cancer control-Lessons to be learned from high-dose rate brachytherapy combined with intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer Brachytherapy 10 2010 286 294
28. N.C. Sheets, G.H. Goldin, and A.M. Meyer Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer JAMA 307 2012 1611 1620
29. A. Shah, J.A. Efstathiou, and J.J. Paly Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy for localized prostate cancer Int J Radiat Oncol Biol Phys 83 2012 e13 e19
30. A. Konski, W. Speier, and A. Hanlon Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol 25 2007 3603 3608
31. B.E. Lewis On equipoise and emerging technologies J Clin Oncol 26 2008 2590
32. F.R. Macbeth, and M.V. Williams Proton therapy should be tested in randomized trials J Clin Oncol 26 2008 2590 2591
33. J.E. Tepper Protons and parachutes J Clin Oncol 26 2008 2436 2437
34. Institute for Clinical and Economic Review, Final Appraisal Document: Brachytherapy and proton beam therapy for treatment of clinically-localized, low-risk prostate cancer. December 22, 2008. www.icer-review.org.
35. K. Hede Research groups promoting proton therapy "lite" J Natl Cancer Inst 98 2006 1682 1684
36. R. de Crevoisier, S.L. Tucker, and L. Dong Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy Int J Radiat Oncol Biol Phys 62 2005 965 973
37. J. Zhang, H. Hricak, and A. Shukla-Dave Clinical stage T1c prostate cancer: evaluation with endorectal MR imaging and MR spectroscopic imaging Radiology 253 2009 425 434
38. B.N. Bloch, E. Furman-Haran, and T.H. Helbich Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging - initial results Radiology 245 2007 176 185
39. Y. Kim, I.C. Hsu, and J. Pouliot Expandable and rigid endorectal coils for prostate MRI: impact on prostate distortion and rigid image registration Med Phys 32 2005 3569 3578
40. B.N. Bloch, R.E. Lenkinski, and N.M. Rofsky The role of magnetic resonance imaging (MRI) in prostate cancer imaging and staging at 1.5 and 3 Tesla: the Beth Israel Deaconess Medical Center (BIDMC) approach Cancer Biomarkers 4 2008 251 262
41. J. Sosna, I. Pedrosa, and W.C. Dewolf MR imaging of the prostate at 3 Tesla: comparison of an external phased-array coil to imaging with an endorectal coil at 1.5 Tesla Acad Radiol 11 2004 857 862
42. D. De Ruysscher, U. Nestle, and R. Jeraj PET scans in radiotherapy planning of lung cancer Lung Cancer 75 2012 141 145
43. J.K. Schwarz, B.A. Siegel, and F. Dehdashti Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma JAMA 298 2007 2289 2295
44. A.I. Arens, E.G. Troost, and D. Schinagl FDG-PET/CT in radiation treatment planning of head and neck squamous cell carcinoma Q J Nucl Med Mol Imaging 55 2011 521 528
45. 18F-choline PET-CT to define a simultaneous integrated boost Strahlenther Onkol 186 2010 600 606
46. 18F-choline PET signal for target volume definition in radiation therapy of the prostate Technol Cancer Res Treat 6 2007 23 30
47. 18F-choline PET-CT detected simultaneous integrated boost Radiother Oncol 93 2009 213 219
48. 18F]-fluoromethylcholine positron emission tomography and 3-T proton magnetic resonance spectroscopy: an experimental study in a rodent rhabdomyosarcoma model Nucl Med Biol 37 2010 645 653
49. 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy BJU Int 99 2007 1415 1420
50. M. Pinkawa, M.J. Eble, and Mottaghy F.M. PET and PET/CT in radiation treatment planning for prostate cancer Exp Rev Anticancer Ther 11 2011 1033 1039
51. M.V. Mishra, C.E. Champ, and R.B. Den Postprostatectomy radiation therapy: an evidence-based review Future Oncol 7 2011 1429 1440
52. G. Giovacchini, M. Picchio, and E. Coradeschi Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy European J Nucl Med Mol Imaging 37 2010 301 309
53. D.A. Kuban, L.B. Levy, and M.R. Cheung Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer Who dies of disease? Int J Radiat Oncol Biol Phys 79 2011 1310 1317
54. M. Ritter Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer Semin Radiat Oncol 18 2008 249 256
55. R. Miralbell, S.A. Roberts, and E. Zubizarreta Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy Int J Radiat Oncol Biol Phys 82 2012 e17 e24
56. C.D. Collins, R.W. Lloyd-Davies, and A.V. Swan Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique Clin Oncol 3 1991 127 132
57. E.E. Yeoh, R.H. Holloway, and R.J. Fraser Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial Int J Radiat Oncol Biol Phys 66 2006 1072 1083
58. H. Lukka, C. Hayter, and J.A. Julian Randomized trial comparing two fractionation schedules for patients with localized prostate cancer J Clin Oncol 23 2005 6132 6138
59. P.A. Kupelian, T.R. Willoughby, and C.A. Reddy Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience Int J Radiat Oncol Biol Phys 68 2007 1424 1430
60. National Institutes of Health. Clinical Trials.gov. 2012.
61. Y. Yamada, L. Rogers, and D.J. Demanes American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy Brachytherapy 11 2012 20 32
62. R. Timmerman, R. Paulus, and J. Galvin Stereotactic body radiation therapy for inoperable early stage lung cancer JAMA 303 2010 1070 1076
63. M.T. Lee, J.J. Kim, and R. Dinniwell Phase I study of individualized stereotactic body radiotherapy of liver metastases J Clin Oncol 27 2009 1585 1591
64. S. Arcangeli, M. Scorsetti, and F. Alongi Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review Crit Rev Oncol Hematol 84 2012 101 108
65. T.P. Boike, Y. Lotan, and L.C. Cho Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer J Clin Oncol 29 2011 2020 2026
66. S.E. Eggener, P.T. Scardino, and P.R. Carroll Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities J Urol 178 2007 2260 2267
67. B. Tareen, G. Godoy, and S.S. Taneja Focal therapy: a new paradigm for the treatment of prostate cancer Rev Urol 11 2009 203 212
68. J. Bellmunt, G. Attard, and A. Bahl Advances in the management of high-risk localised and metastatic prostate cancer BJU Int 109 Suppl 2 2012 8 13
69. A.T. Porter, A.J. McEwan, and J.E. Powe Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer Int J Radiat Oncol Biol Phys 25 1993 805 813
70. E.B. Silberstein Systemic radiopharmaceutical therapy of painful osteoblastic metastases Semin Radiat Oncol 10 2000 240 249
71. S. Nilsson, L. Franzen, and C. Parker Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study Lancet Oncol 8 2007 587 594
72. M. Chhikara, H. Huang, and M.T. Vlachaki Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer Mol Ther 3 2001 536 542
73. B.S. Teh, G. Ayala, and L. Aguilar Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data Int J Radiat Oncol Biol Phys 58 2004 1520 1529
74. Aguilar LK, Teh B, Mai W, et al. Five year follow up of a phase II study of cytotoxic immunotherapy combined with radiation in newly diagnosed prostate cancer. J Clin Oncol. 2006;24 suppl:250s (abstr 4635).
75. H. Haddad, and J.A. Garcia Novel agents for the management of castration-resistant prostate cancer Curr Opin Urol 22 2012 175 182
76. J.L. Gulley, P.M. Arlen, and A. Bastian Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer Clin Cancer Res 11 2005 3353 3362
77. S.E. Finkelstein, F. Rodriguez, and M. Dunn Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy Immunotherapy 4 2012 373 382
78. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
79. M.A. Postow, M.K. Callahan, and C.A. Barker Immunologic correlates of the abscopal effect in a patient with melanoma N Engl J Med 366 2012 925 931
80. S.C. Formenti Immunological aspects of local radiotherapy: clinical relevance Discov Med 9 2010 119 124
81. H. Ishiyama, B.S. Teh, and H. Ren Spontaneous regression of thoracic metastases while progression of brain metastases after stereotactic radiosurgery and stereotactic body radiotherapy for metastatic renal cell carcinoma: abscopal effect prevented by the blood-brain barrier? Clin Genitourinary Cancer 10 2012 196 198
82. S.E. Cotter, G.P. Dunn, and K.M. Collins Abscopal effect in a patient with metastatic Merkel cell carcinoma following radiation therapy: potential role of induced antitumor immunity Arch Dermatol 147 2011 870 872
83. F. Dayyani, G.E. Gallick, and C.J. Logothetis Novel therapies for metastatic castrate-resistant prostate cancer J Natl Cancer Inst 103 2011 1665 1675